

NEWS UPDATE

January 25, 2007

iNovacia announces completion of the first stage of the compound collection.

iNovacia proudly announces the completion of the installation of the first stage of our compound collection. The collection has been carefully expanded from the legend Pharmacia Compound Repository. This has now more than tripled in size and represents a very well curated section of the chemical universe.

The majority of the compounds in the collection were made up from powder in 2007, so purity and identity has recently be checked with the result that more than 90% of the compounds had a higher than 90% purity.

In 2007 we allowed a big Pharma to do a due diligence on our collection in order to have an external validation. The collection was validated and the findings were impressive in that 35% of the compounds were not registered or listed anywhere, 95% passed the acceptance criteria for being allowed into their own library, 79% were not represented in their very extensive collection, and less that 1,5% had been published with any biological data.

Today the collection is maintained in tubes at 10 mM concentration, stored at 4,0 °C with constant nitrogen purge. Removal, thawing, pipetting and handling is done automatically under inert atmosphere, allowing for the compound to be returned to storage within 2 hours of removal.

The compound collection is now being continuously expanded by purchase and internal synthesis, still with the aim to make the collection extremely rich in scaffolds and very accessible for chemical expansion. For this reason, the vast majority of the compounds have full synthetic protocol readily available for immediate production of expansion libraries.

In the expansion, several design criteria are used. The collection should be rich in pharmacophores, lead like and be guided by a desire to be within a "4" range of the Lipinski Guidelines. For the additional library intended for fragment based discovery, different criteria have been applied.

About iNovacia

iNovacia provides drug discovery services to biotech and pharmaceutical companies. Supported by strong chemistry, long-standing experience from drug discovery and an arsenal of biological and biophysical technologies, iNovacia develops discoveries into prototype drugs (leads). Furthermore, iNovacia offers expertise in characterization of proteins and small molecules and develops tools for electronic capturing and analysis experimental data to enhance research out-put. With 34 employees and more than 1,000 m² of instrument-dense laboratories, iNovacia is the largest contract-research organization (CRO) in early drug discovery in the Nordic region. For more information see www.inovacia.se

For further information, please contact

iNovacia AB

Thomas Olin, CEO
+46 8 50 10 30 40 Office
+46 735 20 40 01 Direct
thomas.olin@inovacia.se

Peter Halkjaer-Knudsen, Sr VP
Alliances and Business Development
+46 8 50 10 30 40 Office
+46 735 20 40 35 Direct
hape@inovacia.se